No Detail Found!

Effects of Combined Exercise and GLP-1 Receptor Agonist Liraglutide Therapy on Weight Loss and Metabolic Health in Obese Patients: A Systematic Review and Meta-Analysis

Author(s)
Salma Tamer Abdelrahman Faculty of Medicine, Zagazig University, Zagazig, Egypt
Rehab Ahmed Karam Department of Biochemistry, College of Medicine, Taif University, Saudi Arabia
Nour Ahmed Ezzat Faculty of Medicine, Zagazig University, Zagazig, Egypt
Taqua A. Ezzat Faculty of Medicine, Zagazig University, Zagazig, Egypt
Nourhan Reda Hafez Faculty of Medicine, Zagazig University, Zagazig, Egypt
Alaa E. Younes Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
Abdullah Al-Sawat Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
Khalid Mohammed Alzahrani Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
Owaid M. Almalki Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
Tamer M. Abdelrahman Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia
Abstract
Objectives: The benefits of using liraglutide with exercise in obesity therapy are not yet well defined. To conduct a systematic review on the influence of the use of liraglutide and exercise on weight loss and body composition in obese patients. Methods: A systematic review and meta-analysis were done on Randomized Controlled Trials (RCTs) following the guidelines of PRISMA and registered in PROSPERO (CRD420251234320). Relevant databases and clinical trial registries were searched up till 2025. Eligible studies included adults (eighteen to sixty-five years) with obesity, comparing combined (moderate-to-vigorous) exercise and liraglutide therapy with placebo or usual care. Body weight change was the primary outcome assessed. Secondary outcomes included waist circumference, body fat percentage, Insulin Resistance (HOMA-IR), glycemic markers and lipid profile parameters. Results: Seven RCTs comprising up to 562 participants were included. Combined exercise and liraglutide therapy resulted in significantly greater weight loss than controls (WMD -8.21 kg; 95% CI -11.35 to -5.07; p<0.00001), with substantial heterogeneity (I² = 87%), likely reflecting differences in study populations, liraglutide doses and comparator interventions. Sensitivity analysis excluding two clinically distinct trials (Mensberg et al . and Wadden et al .) eliminated heterogeneity (I² = 0%) and confirmed robust effects (WMD -10.34 kg; 95% CI -11.95 to -8.74). Significant reductions were also observed in body fat percentage, waist circumference and HOMA-IR. Conclusion: Combined exercise and liraglutide therapy produce clinically meaningful improvements in body weight, anthropometric indices and insulin sensitivity in obese adults, exceeding the effects of either intervention alone. However, these findings should be interpreted with caution due to the small number of included studies and the variability observed among the trials.
Publication Details
Page(s) 91-100
Published Journal: Journal of Pioneering Medical Sciences, Volume: 15, Issue: 6, Year: 2026

Request the full text from PASTIC

Keywords
Exercise, Obesity, Weight loss, Glucagon-Like Peptide-1 Receptor Agonists, Exercise, Liraglutide
References
Mathew H. .2017 ."Adipose tissue and reproductive health." Metabolism: Clinical and Experimental. , 11 : 18-32.
Hariharan R. .2022 ."The dietary inflammatory index, obesity, type 2 diabetes and cardiovascular risk factors and diseases. " Obesity Reviews, 23(1) : .
Boutari C.,Mantzoros C.S. .2022 ."A 2022 update on the epidemiology of obesity and a call to action: As its twin COVID-19 Pandemic appears to be receding, the obesity and dysmetabolism pandemic continues to rage on." Metabolism: Clinical and Experimental. , 155217 : .
Sindhwani R. . ."The dual challenge of diabesity: pathophysiology, management and future directions." NaunynSchmiedeberg's Archives of Pharmacology. , 398(2025) : 4891-4912.
Kloock S. .2023 ."Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?" Pharmacology and Therapeutics. , 108549 : .
Kheniser K. . ."Long-Term weight loss strategies for obesity.". The Journal of Clinical Endocrinology & Metabolism, 106(2021) : 1854-1866.
Jalleh R.J. . ."Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide.". The Journal of Clinical Endocrinology & Metabolism, 110(2024) : 1-15.
Rubio-Herrera M. .2023 ."Impact of treatment with GLP-1 receptor agonists, liraglutide 3.0 mg and semaglutide 1.0 mg, while on a waiting list for bariatric surgery. " Biomedicines, 2785(10) : .
Alyassi A. .2024 ."GLP-1 receptor agonists as a breakthrough therapy for obesity and metabolic syndrome: A systematic review of efficacy and long-term outcomes. " Journal of Population Therapeutics and Clinical Pharmacology, 31(11) : 1915-1925.
Blüher M. . ."New insights into the treatment of obesity. " Diabetes, Obesity and Metabolism, 25(2023) : 2058-2072.
Oppert J.M. .2021 ."Exercise training in the management of overweight and obesity in adults: Synthesis of the evidence and recommendations from the European association for the study of obesity physical activity working group. " Obesity Reviews, 22(suppl) : .
Jensen S.B.K. .2024 ."Healthy weight loss maintenance with exercise, GLP-1 receptor agonist, or both combined followed by one year without treatment: A post-treatment analysis of a randomised placebo-controlled trial. " EClinicalMedicine, 102475 : .
Sandsdal R.M. .2023 ."Combination of exercise and GLP-1 receptor agonist treatment reduces severity of metabolic syndrome, abdominal obesity and inflammation: A randomized controlled trial. " Cardiovascular Diabetology, 41(1) : .
Jensen S.B.K. .2022 ."Exploratory analysis of eating- and physical activity-related outcomes from a randomized controlled trial for weight loss maintenance with exercise and liraglutide single or combination treatment.". Nature Communications, 4770(1) : .
Mensberg P. . ."Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes." Diabetes, Obesity and Metabolism. , 19(2017) : 172-180.
Lundgren J.R. .2021 ."Healthy weight loss maintenance with exercise, liraglutide, or both combined.". The New England Journal of Medicine, 384(18) : 1719-1730.
Jensen S.B.K. . ."Weight loss maintenance with exercise and liraglutide improves glucose tolerance, glucagon response and beta cell function. " Obesity, 31(2023) : 977-989.
Wadden T.A. . ."Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for obesity in primary care: The SCALE IBT randomized controlled trial. " Obesity, 28(2020) : 529-536.
Choi G.J. and H.,Kang G.J. and H. . ."Heterogeneity in meta-analyses: An unavoidable challenge worth exploring.". Korean Journal of Anesthesiology, 78(2025) : 301-314.
Khera R. .2016 ."Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. " JAMA, 7602(22) : 2424-2434.
Swift D.L. .2013 ."The role of exercise and physical activity in weight loss and maintenance." Progress in Cardiovascular Diseases. , 09(2014) : 441-447.
Rosenbaum M.,Leibel R.L. .2010 ."Adaptive thermogenesis in humans.". International Journal of Obesity, 184(2010) : S47-S55.
Moiz A. .2025 ."Mechanisms of GLP-1 receptor agonistinduced weight loss: A review of central and peripheral pathways in appetite and energy regulation. " The American Journal of Medicine, 01(2025) : 934-940.
Małkowska P. . ."Positive effects of physical activity on insulin signaling." Current Issues in Molecular Biology. , 46(2024) : 5467-5487.
Cava E. . ."Preserving healthy muscle during weight loss." Advances in Nutrition. , 8(2017) : 511-519.
Ross R. . ."Waist circumference as a vital sign in clinical practice: A Consensus statement from the IAS and ICCR working group on visceral obesity." Nature Reviews Endocrinology. , 16(2020) : 177-189.
Zhao X. .2023 ."The crucial role and mechanism of insulin resistance in metabolic disease." Frontiers in Endocrinology. , 1149239 : .
Liu J. . ."Liraglutide and exercise synergistically attenuate vascular inflammation and enhance metabolic insulin action in early diet-induced obesity. " Diabetes, 72(2023) : 0745-931.
0

Citations

0

Downloads

14

Views